FDA Brief

Warning letters Drugs

FDA warning letter to

Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

High riskIssued Jul 10Posted Jul 21Center for Drug Evaluation and Research (CDER)

FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

What happened

FDA inspected the Alembic Research Centre in Vadodara, Gujarat, India, from March 3 to 7, 2025, as part of its Bioresearch Monitoring Program, reviewing a clinical in vivo bioequivalence study of an investigational drug. The agency found that the 'Nature and Purpose of this Study' section of the informed consent form said the study was a clinical research project 'but no part of it is of an experimental nature.' The company responded on March 26, 2025, but FDA called the response inadequate because it lacked details on how the investigator would comply with consent rules and did not include the revised consent forms with Ethics Committee approval.

What FDA found

  1. The consent form told subjects that no part of the study was experimental, which could mislead them about what they were agreeing to.

    21 CFR 312.60 and 21 CFR 50.20
  2. The consent form did not clearly describe the experimental nature of the study, which the basic elements of informed consent require.

    21 CFR 50.25(a)(1)

What FDA wants

Within 15 business days, the investigator must write to FDA describing actions taken to prevent similar violations, including how he will ensure compliance with the informed consent rules. FDA also asked for the revised consent forms with Ethics Committee approval for all ongoing and planned studies, which the earlier response did not include.

Who should pay attention

  • clinical investigators running bioequivalence studies
  • sites and contract research organizations that draft consent forms
  • drug sponsors that rely on this site's study data in applications

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  3. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

    FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

    High risk
  4. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk